Amylyx Pharmaceuticals (AMLX) Change in Accured Expenses (2022 - 2026)

Amylyx Pharmaceuticals' Change in Accured Expenses history runs 5 years deep, the most recent figure standing at -$6.7 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 43.83% year-over-year to -$6.7 million; the TTM figure through Mar 2026 stood at -$1.4 million (up 97.83% YoY), while the FY2025 annual figure was -$6.6 million, up 88.97% from the prior year.
• Change in Accured Expenses was -$6.7 million for Q1 2026 at Amylyx Pharmaceuticals, down from -$1.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $20.8 million in Q4 2023 to a low of -$26.4 million in Q4 2024.
• Historically, Change in Accured Expenses has averaged -$2.6 million across 5 years, with a median of -$676500.0 in 2023.
• The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses plunged 8879.45% in 2024, then jumped 143.08% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at $5.7 million in 2022, then surged by 267.58% to $20.8 million in 2023, then tumbled by 227.07% to -$26.4 million in 2024, then jumped by 95.42% to -$1.2 million in 2025, then tumbled by 452.03% to -$6.7 million in 2026.
• The last three Change in Accured Expenses figures came in at -$6.7 million (Q1 2026), -$1.2 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.